Yahoo! Finance Search - Finance Home - Yahoo! - Help

Thursday, March 23 2017 12:19pm ET - U.S. Markets close in 3 hours and 41 minutes.
Industry Center - Biotechnology & Drugs
Industry Center > Biotechnology & Drugs > News
More On This Industry
· Summary
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Healthcare Facilities
· Investment Services
· Major Drugs
· Medical Equipment & Supplies
· Retail (Drugs)
· Scientific & Technical Instr.
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Biotechnology & Drugs News
View: Latest News | Top Stories
1. Alkermes Drug Gets Priority FDA Review - AP - Fri May 27, 2005
Pharmaceutical company Alkermes Inc. on Friday said its new drug application for its alcohol dependence medication has been accepted and granted a priority review by the Food and Drug Administration.
2. Biovail Gets Tentative FDA OK for Pill - AP - Fri May 27, 2005
Canadian pharmaceutical company Biovail Corp. said Friday that it received tentative approval from the Food and Drug Administration for an orally-disintegrating version of Sanofi-Aventis SA's Ambien sleeping pill.
3. Market Pulse: Biovail gets tentative ok for generic version of Ambien - at MarketWatch - Fri May 27, 2005
4. Santarus Submits New Drug Application for ZEGERID Chewable Tablets - Business Wire - Fri May 27, 2005
Santarus, Inc. , a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that it has submitted a New Drug Application for ZEGERID Chewable Tablets 40 mg and 20 mg to the U.S.
5. Neurocrine Announces Submission of New Drug Application for Indiplon Tablets - PR Newswire - Thu May 26, 2005
Neurocrine Biosciences, Inc. announced that the company has completed submission of a New Drug Application to the U.S. Food and Drug Administration for indiplon tablets for the treatment of insomnia in both adult and elderly patients.
6. FDA Approves IND for Elite Pharmaceuticals Abuse-Resistant Oxycodone Product - PR Newswire - Thu May 26, 2005
Elite Pharmaceuticals, Inc. announced that the FDA has approved the Company's investigational new drug application for its abuse-resistant oxycodone product.
7. Elan Holds Its Ground - Motley Fool - Thu May 26, 2005
Elan clearly isn't throwing in the towel on Tysabri, but its fate is not solely in the company's hands.
8. Flu Vaccines' Unhealthy Competition - Motley Fool - Thu May 26, 2005
New competitors in the flu-fighting niche could make all companies worse off.
9. Market Pulse: Eyetech upped at Thomas Weisel, Lucentis cited - at MarketWatch - Thu May 26, 2005
10. Law Firm Shalov Stone & Bonner LLP Announces Class Action Lawsuit Against Able Laboratories, Inc. - Business Wire - Wed May 25, 2005
On May 24, 2005, a class action was commenced on behalf of all persons who purchased the securities of Able Laboratories, Inc. , in the period from May 6, 2003, through May 18, 2005.

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Biotechnology & Drugs Headlines
More Finance RSS Feeds

Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?